Cathy Eng, MD, FACP, FASCO, discusses how oncology fellows can navigate the journal submission and review process.
|Articles|January 11, 2013
Unraveling the Layers: IDNs, ACOs, and the Future of Healthcare Integration
Author(s)HRA
This recorded webinar features thought leader perspectives and key insights from HRA's newest research program - Understanding Integrated Delivery Networks.
Advertisement
This recorded webinar features thought leader perspectives and key insights from HRA's newest research program - Understanding Integrated Delivery Networks.
- The webinar covers key issues in healthcare integration, including: the changing healthcare landscape and the need for integration.
- Defining the IDN, ACO, and PCMH
- Why IDN, ACO, and PCMH are important customer segments and how they are evolving
- How IDNs, ACOs, and PCMHs intersect and where is it going in the future
- The current and future role of the payor in an integrated environment
- The impact of Healthcare Reform on integration
- Identifying the customer, and appropriate contracting strategies.
Advertisement
Related to this article
The FDA has granted fast track designation to varsetatug masetecan for relapsed/refractory metastatic colorectal cancer.
SYS6090, a first-in-class PD-1/IL-15 bispecific fusion protein, earned fast track status for MSS/pMMR metastatic colorectal cancer that has progressed on standard systemic therapy.
ASCO issued an alert regarding dwindling supplies of ifosfamide, which is used across testicular cancer and sarcoma regimens.
The WVU Heart and Vascular Institute and WVU Cancer Institute performed West Virginia’s first single-port robotic-assisted thoracoscopic lobectomy.
The FDA approval of daraxonrasib was based on data from the phase 3 RASolute 302 trial in previously treated metastatic pancreatic ductal adenocarcinoma.
SOT106 earned an FDA fast track designation for advanced or recurrent soft tissue sarcoma.
The sNDA is supported by VIKTORIA-1 Study 2 data showing that gedatolisib-based regimens approximately doubled median PFS vs alpelisib plus fulvestrant.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
2
Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAC
3
ASCO Issues Warning Regarding Ifosfamide Shortage for Cancer Care
4
Dr Ayanambakkam on the Safety of Darlifarnib Plus Cabozantinib in RCC KD
5